Specialist Updates

New option for severe asthma in kids

A leading respiratory physician has welcomed the new PBS listing for omalizumab (Xolair) which will give children from six years and over access to the drug for severe allergic asthma.

The therapy was previously subsidised only for children over the age of 12 with symptoms inadequately controlled with high dose preventer medications.

Lowering the age threshold will provide a much needed third-line option for younger children, says